OncoMatch/Clinical Trials/NCT05489289
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
Is NCT05489289 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies AK104 for hepatocellular carcinoma.
Treatment: AK104 — The efficacy and safety of AK104 as adjuvant therapy in hepatocellular carcinoma of high recurrence risk after curative resection.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–0(Fully active)
Prior therapy
Must have received: radical surgery — curative resection
Receiving radical resection as the only anti-tumor treatment
Cannot have received: any anti-tumor treatment other than radical surgery
Any anti-tumor treatment other than radical surgery before randomization
Lab requirements
Liver function
Child-Pugh grade: A; Precarious liver function indicated by severe complications [excluded]
Cardiac function
Poorly controlled or symptomatic hypertension, congestive heart failure, arrhythmia, etc [excluded]
Child-Pugh grade: A; Precarious liver function indicated by severe complications [excluded]; Poorly controlled or symptomatic hypertension, congestive heart failure, arrhythmia, etc [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify